An eye-popping bill for just a handful of specialty medications is in the pipeline for the federal government—and therefore, taxpayers—in the next 10 years, the health insurance industry’s lead trade group warned Monday.
“We are witnessing a return to dramatic increases of year-to-year drug spending,” said Dan Durham, interim CEO of America’s Health Insurance Plans.
The research, commissioned by AHIP and prepared by the Avalere Health consulting group, projects the federal government in the next decade will have to spend almost $50 billion on just 10 so-called breakthrough medications alone, with most of those drugs having yet to hit the market.
Hey, check out all the research scientist jobs. Post your resume today!
